You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
研報掘金丨申萬宏源:維持藥明康德“買入”評級,訂單加速增長,特別分紅+回購持續回饋股東
格隆匯 03-21 14:49

申萬宏源研究指出,藥明康德(603259.SH)24年歸母淨利潤94.5億元,同比下降1.63%,經調整歸母淨利潤105.8億元,同比下降2.5%;24Q4經調整歸母淨利潤32.4億元,同比增長20.4%,環比增長9.1%,業績符合公司指引。公司訂單加速增長,特別分紅+回購持續回饋股東。公司為全球醫藥行業提供一體化、端到端的新藥研發和生產服務,通過獨特的“CRDMO”和“CTDMO”業務模式,不斷降低研發門檻。根據公司PPT,公司預計2025年持續經營業務收入重回雙位數增長,同比增長10%-15%,公司整體收入達到415-430億,維持“買入”評級。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account